惠尔血治疗消化道癌化疗后白细胞减少症的临床观察

观察采取先大剂量后小剂量基因重组人粒细胞集落刺激因子（Ｇ－ＣＳＦ）,治疗消化道癌化疗后白细胞减少症的临床效果。对３０例患者进行前瞻性分组,初次化疗组和重复化疗组。化疗后４８ｈ以上,如果两次血常规检查白细胞数＜３．０×１０９／Ｌ,则采用惠尔血治疗。先大剂量皮下注射,待白细胞≥１０．０×１０９／Ｌ后,剂量减半维持７～１０天。治疗效果总有效率为９６．６％,６天内白细胞数１０．０×１０９／Ｌ的比率,初次化疗组明显高于重复化疗组。该实验提示采用先大剂量后小剂量惠尔血（Ｇ－ＣＳＦ）治疗消化道癌化疗后白细胞减少症有良好疗效。

Effect of G-CSF in Treatment of Postchemotherapy Leukopenia

Objective: To observe the effect of G-CSF (GRAN) in the treatment of leukopenia after chemotherapy of digestive tract cancer. Methods: A prospective observation was made in 30 patients (28 digestive tract cancer patients and 2 lung cancer patients). Eleven of them was receiving first line chemotherapy and 19 were under repeated chemotherapy. GRAN (150-300g/day hypodermic injection) was administrated to the patients when their WBC went down < 3.0 109/L at routine blood test at two times 48 hrs after chemotherapy. When WBC returned to 10.0 109/L,dosage of GRAN was reduced to half for 7-10 days. In instances when WBC remained < 4.0 109/L after having used GRAN 10 days, it was judged a failure . Results: The total effective rate was 96.6%. Effect due to GRAN in patients for the first time receiving chemotherapy was excellent, the rate of WBC in excess of >10.0109/L at the 6th day was 81.8%, while it was only 36.8%in patients under repeated chemotherapy. Conclusion: GRAN is very effective in the treatment of leukopenia after chemotherapy for digestive tract cancer.